Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
Department of Gastroenterology, John Hunter Hospital, New Lambton, New South Wales, Australia.
Carla
C
Silva
Department of Gastroenterology, John Hunter Hospital, New Lambton, New South Wales, Australia.
Elizabeth
E
Ianna
Department of Gastroenterology, John Hunter Hospital, New Lambton, New South Wales, Australia.
Tracey
T
Jones
Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT, Australia; and Department of Infectious Diseases, John Hunter Hospital, New Lambton Heights NSW, Australia.
Joshua S
JS
Davis
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects*
D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a